Holen Sie sich die Stockscreener-App
6.37
2.41%
0.15
Handel nachbörslich:
6.50
0.13
+2.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MYGN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$6.22
Offen:
$6.25
24-Stunden-Volumen:
2.25M
Relative Volume:
1.24
Marktkapitalisierung:
$592.69M
Einnahmen:
$823.60M
Nettoeinkommen (Verlust:
$-116.00M
KGV:
-4.90
EPS:
-1.3
Netto-Cashflow:
$-107.30M
1W Leistung:
+5.81%
1M Leistung:
+55.37%
6M Leistung:
-42.41%
1J Leistung:
-77.51%
1-Tages-Spanne:
$6.21
$6.56
1-Wochen-Bereich:
$5.78
$6.56
52-Wochen-Spanne:
$3.76
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
Firmenname
Myriad Genetics Inc
Sektor
Branche
Telefon
801-584-3600
Adresse
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Vergleichen Sie MYGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
6.37 | 578.74M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
492.72 | 184.93B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
205.82 | 147.00B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
647.09 | 51.77B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
125.66 | 35.50B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
190.81 | 32.08B | 15.70B | 1.24B | 2.01B | 6.91 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-21 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-12 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | Eingeleitet | Craig Hallum | Buy |
| 2024-12-10 | Eingeleitet | UBS | Neutral |
| 2024-12-09 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Underperform |
| 2024-05-08 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Underweight |
| 2023-05-23 | Hochstufung | Goldman | Sell → Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Eingeleitet | Stephens | Equal-Weight |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Sell |
| 2019-09-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Herabstufung | Needham | Strong Buy → Hold |
| 2019-07-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-03-12 | Bestätigt | Needham | Strong Buy |
| 2019-01-03 | Eingeleitet | Needham | Strong Buy |
| 2018-11-30 | Hochstufung | Goldman | Sell → Neutral |
| 2018-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Eingeleitet | Goldman | Sell |
| 2018-01-22 | Bestätigt | Barclays | Equal Weight |
| 2018-01-05 | Eingeleitet | BTIG Research | Buy |
| 2017-10-02 | Fortgesetzt | Leerink Partners | Mkt Perform |
| 2017-08-09 | Bestätigt | Barclays | Equal Weight |
| 2017-02-08 | Hochstufung | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Sell |
| 2016-10-10 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
Alle ansehen
Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten
What recovery options are there for Myriad Genetics Inc.Sell Signal & AI Enhanced Trade Execution Alerts - Newser
How does Myriad Genetics Inc. compare to its peersJuly 2025 Big Picture & Detailed Earnings Play Strategies - خودرو بانک
Real time alert setup for Myriad Genetics Inc. performancePortfolio Gains Summary & Fast Gain Swing Trade Alerts - Newser
Predicting Myriad Genetics Inc. trend using moving averages2025 Dividend Review & Consistent Return Strategy Ideas - Newser
Combining machine learning predictions for Myriad Genetics Inc.CEO Change & Long-Term Capital Growth Strategies - Newser
How to use Fibonacci retracement on Myriad Genetics Inc.2025 Market Trends & Weekly Market Pulse Updates - Newser
Can volume confirm reversal in Myriad Genetics Inc.Trade Volume Summary & Fast Entry High Yield Tips - Newser
What Fibonacci levels say about Myriad Genetics Inc. rebound2025 Technical Overview & Weekly High Return Stock Forecasts - Newser
Is Myriad Genetics Inc. stock entering bullish territoryShare Buyback & Verified Trade Idea Suggestions - Newser
Will Myriad Genetics Inc. see short term momentum2025 Trading Recap & Real-Time Chart Pattern Alerts - Newser
Can Myriad Genetics Inc. recover in the next quarter2025 Trading Recap & AI Driven Price Predictions - Newser
Custom strategy builders for tracking Myriad Genetics Inc.Dollar Strength & High Yield Equity Trading Tips - Newser
Using AI based signals to follow Myriad Genetics Inc.July 2025 Summary & Comprehensive Market Scan Reports - Newser
Myriad Genetics Inc. stock trend forecastQuarterly Portfolio Report & Long-Term Investment Growth Plans - Newser
Will Myriad Genetics Inc. continue its uptrend2025 Investor Takeaways & Daily Stock Trend Watchlist - Newser
Myriad Genetics Inc. stock prediction for this weekMarket Rally & Weekly Stock Performance Updates - Newser
Published on: 2025-08-30 20:52:01 - Newser
How to monitor Myriad Genetics Inc. with trend dashboardsRisk Management & Precise Entry and Exit Recommendations - Newser
Historical volatility pattern of Myriad Genetics Inc. visualizedMarket Risk Report & Consistent Income Trade Recommendations - Newser
Myriad Genetics Soars 9.64% to 2025 High on Leadership Shift, Institutional Buys and Earnings Beat - AInvest
Regression analysis insights on Myriad Genetics Inc. performanceGap Up & Safe Capital Allocation Plans - Newser
Finanzdaten der Myriad Genetics Inc-Aktie (MYGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):